

<b>Impact Assessment</b>	<b>Impact Category</b>	<b>Definition</b>
<b>Trial categories of special interests</b>	Novel Therapy	Trials involving newly developed intervention
	Rare Cancer Setting	Cancer that occurs in <6 out of 100,000 people each year. Very rare pediatric cancers occur in <2 out of 1,000,000 children each year.
	Patient Management	Patient education, awareness, self- assessment trials, symptom control, improving patient experience
	Vulnerable Populations	Pediatric, AYA, elderly, organ dysfunction
	Lifestyle Interventions	Trials focused on lifestyle changes that may prevent, decrease severity and/or delay disease progression and treatment side effects (e.g. exercise, diet)
	Precision Medicine	Biomarker, immunotherapy, diagnosis, and targeted therapies
<b>Potential Impact on Patient Population</b>	Breakthrough Trial	Trial involving a first in class, or novel intervention (drug, biologic, technology or technique) that could dramatically change how people with a particular type of cancer are treated
	Platform Trial	Using already available (e.g. FDA approved) interventions for new combination, new types, settings or stages of cancer
	Enhancement/ Derivative Trial	Using additional targeting biomarker screening to tailor treatment and investigate outcomes
	Sustaining Trial	Calibrating/focusing on dosages, treatment cycles or schedule
	Cross Cancer Trial	Results applied to multiple disease sites or basket/umbrella trials
<b>Innovativeness of Trials</b>	Incremental	Potential for iterative changes/advancement
	Paradigm Shifting	Potential for radical improvements in cancers/policy changes within cancer, or across a cancer spectrum
<b>Study Results</b>	Positive/Negative	Based on comparison of published results with the study primary outcome/end points